Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 4/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091982 | 1.00 | HTR2B (0.34) | HTR2BMETHRH3HRH1CCR3 | |
| SCHEMBL1093124 | 0.90 | FASN (0.37) | METHRH3HRH1CCR3MEN1 | |
| SCHEMBL1093126 | 0.90 | FASN (0.37) | METHRH3HRH1CCR3MEN1 | |
| SCHEMBL1092804 | 0.89 | ALDH1A1 (0.41) | METHRH3HRH1KMT2AHPGD | |
| SCHEMBL1092806 | 0.89 | ALDH1A1 (0.41) | METHRH3HRH1KMT2AHPGD | |
| SCHEMBL208582 | 0.88 | MET (0.36) | HTR2BMETHRH3HRH1CCR3 | |
| SCHEMBL208581 | 0.88 | MET (0.36) | HTR2BMETHRH3HRH1CCR3 | |
| SCHEMBL208583 | 0.88 | MET (0.36) | HTR2BMETHRH3HRH1CCR3 | |
| SCHEMBL209140 | 0.88 | MET (0.36) | HTR2BMETHRH3HRH1CCR3 | |
| SCHEMBL1092603 | 0.86 | CHRM2 (0.37) | SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153807-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2021336-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BUSH JULIE KAY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111809-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | HTR2B 897/4885MET 2215/4885HRH3 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.